A
Adrian B. McDermott
Researcher at National Institutes of Health
Publications - 206
Citations - 16232
Adrian B. McDermott is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Antibody & Medicine. The author has an hindex of 50, co-authored 152 publications receiving 10254 citations. Previous affiliations of Adrian B. McDermott include Aaron Diamond AIDS Research Center & University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson,Evan J. Anderson,Nadine Rouphael,Paul C. Roberts,Mamodikoe Makhene,Rhea N. Coler,Michele Paine McCullough,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Nicole A. Doria-Rose,Kizzmekia S. Corbett,Kaitlyn M. Morabito,Sijy O’Dell,Stephen D. Schmidt,Phillip A. Swanson,Marcelino Padilla,John R. Mascola,Kathleen M. Neuzil,Hamilton Bennett,Wellington Sun,Etza Peters,Mat Makowski,Jim Albert,Kaitlyn Cross,Wendy Buchanan,Rhonda Pikaart-Tautges,Julie E. Ledgerwood,Barney S. Graham,John H. Beigel +32 more
TL;DR: The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Journal ArticleDOI
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Evan J. Anderson,Nadine Rouphael,Alicia T. Widge,Lisa A. Jackson,Paul C. Roberts,Mamodikoe Makhene,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Bob C. Lin,Nicole A. Doria-Rose,Sijy O'Dell,Stephen D. Schmidt,Kizzmekia S. Corbett,Phillip A. Swanson,Marcelino Padilla,Kathy M. Neuzil,Hamilton Bennett,Brett A. Leav,Mat Makowski,Jim Albert,Kaitlyn Cross,Venkata Viswanadh Edara,Katharine Floyd,Mehul S. Suthar,David R. Martinez,Ralph S. Baric,Wendy Buchanan,Catherine J. Luke,Varun K Phadke,Christina A. Rostad,Julie E. Ledgerwood,Barney S. Graham,John H. Beigel +36 more
TL;DR: The phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein in healthy adults found it induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100- μg dose in a phase 3 vaccine trial.
Journal ArticleDOI
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
Kizzmekia S. Corbett,Barbara J. Flynn,Kathryn E. Foulds,Joseph R. Francica,Seyhan Boyoglu-Barnum,Anne P. Werner,Britta Flach,Sarah O’Connell,Kevin W. Bock,Mahnaz Minai,Bianca M. Nagata,Hanne Leth Andersen,David R. Martinez,Amy T. Noe,Naomi Douek,Mitzi M. Donaldson,Nadesh N Nji,Gabriela S. Alvarado,Darin K. Edwards,Dillon R. Flebbe,Evan Lamb,Nicole A. Doria-Rose,Bob C. Lin,Mark K. Louder,Sijy O'Dell,Stephen D. Schmidt,Emily Phung,Lauren A. Chang,Christina Yap,John-Paul Todd,Laurent Pessaint,Alex Van Ry,Shanai Browne,Jack Greenhouse,Tammy Putman-Taylor,Amanda Strasbaugh,Tracey-Ann Campbell,Anthony Cook,Alan Dodson,Katelyn Steingrebe,Wei Shi,Yi Zhang,Olubukola M. Abiona,Lingshu Wang,Amarendra Pegu,Eun Sung Yang,Kwanyee Leung,Tongqing Zhou,I-Ting Teng,Alicia T. Widge,Ingelise J. Gordon,Laura Novik,Rebecca A. Gillespie,Rebecca J. Loomis,Juan I. Moliva,Guillaume Stewart-Jones,Sunny Himansu,Wing-Pui Kong,Martha Nason,Kaitlyn M. Morabito,Tracy J. Ruckwardt,Julie E. Ledgerwood,Martin R. Gaudinski,Peter D. Kwong,John R. Mascola,Andrea Carfi,Mark G. Lewis,Ralph S. Baric,Adrian B. McDermott,Ian N. Moore,Nancy J. Sullivan,Mario Roederer,Robert A. Seder,Barney S. Graham +73 more
TL;DR: Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung.
Journal ArticleDOI
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Alicia T. Widge,Nadine Rouphael,Lisa A. Jackson,Evan J. Anderson,Paul C. Roberts,Mamodikoe Makhene,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Bob C. Lin,Nicole A. Doria-Rose,Sijy O'Dell,Stephen D. Schmidt,Kathleen M. Neuzil,Hamilton Bennett,Brett Leav,Mat Makowski,Jim Albert,Kaitlyn Cross,Venkata Viswanadh Edara,Katharine Floyd,Mehul S. Suthar,Wendy Buchanan,Catherine J. Luke,Julie E. Ledgerwood,John R. Mascola,Barney S. Graham,John H. Beigel +30 more
TL;DR: A small number of adults received two 100-μg injections of Moderna’s mRNA SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody titers revealed immunogenicity and safety concerns.
Journal ArticleDOI
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
Nicole A. Doria-Rose,Mehul S. Suthar,Mat Makowski,Sarah O’Connell,Adrian B. McDermott,Britta Flach,Julie E. Ledgerwood,John R. Mascola,Barney S. Graham,Bob C. Lin,Sijy O'Dell,Stephen D. Schmidt,Alicia T. Widge,Venkata Viswanadh Edara,Evan J. Anderson,Evan J. Anderson,Lilin Lai,Katharine Floyd,Nadine Rouphael,Veronika I. Zarnitsyna,Paul C. Roberts,Mamodikoe Makhene,Wendy Buchanan,Catherine J. Luke,John H. Beigel,Lisa A. Jackson,Kathleen M. Neuzil,Hamilton Bennett,Brett Leav,Jim Albert,Pratap Kunwar +30 more
TL;DR: A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months.